XBIT

XBiotech, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website xbiotech.com
Employees(FY) 85
ISIN CA98400H1029

Performance

-8.38%

-17.11%

-54.13%

-54.37%

-14.18%

YTD

-26.14%

Profile

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Advanced Technical Analysis

Technical Analysis of XBIT 2025-01-31

The stock indicators suggest a mixed sentiment, with a bearish Moving Average Score of 3 and a neutral Oscillators Score of 46, while the Technical Score of 7 reinforces the overall bearish outlook. This combination indicates a lack of strong bullish momentum, signaling caution for potential investors.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of XBIT

Stock Rank

Recent News & Updates

2025-01-14 03:37
Wolf Haldenstein Adler Freeman and Herz LLP announces that it is investigating XBiotech for potential violations of securities laws(Globenewswire)
2024-12-22 20:00
XBiotech Pauses Rheumatology program(Globenewswire)
2024-08-12 02:45
XBiotech: Q2 Earnings Snapshot(Yahoo Finance)
2024-06-17 23:35
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer(Globenewswire)
2024-05-12 22:53
XBIT Stock Earnings: XBiotech Reported Results for Q1 2024(Investorplace)
2024-05-10 01:05
XBiotech: Q1 Earnings Snapshot(Yahoo Finance)
2024-03-18 03:53
XBIT Stock Earnings: XBiotech Reported Results for Q4 2023(Investorplace)
2024-01-03 20:00
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus(Yahoo Finance)
2023-11-13 20:00
Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid Arthritis(Globenewswire)
2023-09-25 21:00
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke(Yahoo Finance)
2023-08-29 21:00
XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer(Yahoo Finance)
2023-08-07 23:47
XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial(Yahoo Finance)
2023-07-24 23:53
The past three years for XBiotech (NASDAQ:XBIT) investors has not been profitable(Yahoo Finance)
2023-06-27 22:36
Here's Why We're Not Too Worried About XBiotech's (NASDAQ:XBIT) Cash Burn Situation(Yahoo Finance)
2023-05-21 21:00
FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients(Yahoo Finance)
2023-05-16 21:00
XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares(Yahoo Finance)
2023-04-16 21:00
XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke(Yahoo Finance)
2023-04-08 22:08
XBiotech Inc.'s (NASDAQ:XBIT) top owners are individual investors with 51% stake, while 36% is held by insiders(Yahoo Finance)
2023-02-14 20:29
The past three years for XBiotech (NASDAQ:XBIT) investors has not been profitable(Yahoo Finance)
2023-01-18 19:02
XBiotech (NASDAQ:XBIT) Is In A Good Position To Deliver On Growth Plans(Yahoo Finance)
2022-11-10 16:00
XBiotech Third Quarter 2022 Earnings: US$0.42 loss per share (vs US$0.11 loss in 3Q 2021)(Yahoo Finance)
2022-10-30 21:41
Insiders own 35% of XBiotech Inc. (NASDAQ:XBIT) shares but individual investors control 47% of the company(Yahoo Finance)
2022-10-13 00:46
XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix Therapy for Colorectal Cancer(Yahoo Finance)
2022-09-07 20:59
XBiotech (NASDAQ:XBIT) shareholders have endured a 73% loss from investing in the stock a year ago(Yahoo Finance)
2022-08-11 20:38
We Think XBiotech (NASDAQ:XBIT) Can Afford To Drive Business Growth(Yahoo Finance)
2022-06-19 21:00
XBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer Study(Yahoo Finance)
2022-05-23 21:06
Could The XBiotech Inc. (NASDAQ:XBIT) Ownership Structure Tell Us Something Useful?(Yahoo Finance)
2022-04-27 21:00
XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Phase I/II/III Clinical Study for Natrunix in Combination with Trifluridine/Tipiracil (TASKIN) for Treatment of Metastatic Colorectal Cancer(Yahoo Finance)
2022-03-14 23:00
XBiotech (NASDAQ:XBIT) shareholders have endured a 48% loss from investing in the stock a year ago(Yahoo Finance)
2022-02-01 20:00
XBiotech Inks Clinical Manufacturing Deal(Yahoo Finance)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.